| 1 |
19112166 | Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. | 2009 Mar |
1 |
| 2 |
19199981 | Pleiotropic effects of rimonabant: clinical implications. | 2009 |
1 |
| 3 |
19275673 | The endocannabinoid system: a promising target for the management of type 2 diabetes. | 2009 Feb |
1 |
| 4 |
18303686 | [Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system]. | 2008 Jan |
1 |
| 5 |
18426513 | CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. | 2008 May |
1 |
| 6 |
17392496 | The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. | 2007 May |
1 |
| 7 |
18054734 | Cannabinoid-1 receptor antagonists in type-2 diabetes. | 2007 Dec |
1 |
| 8 |
18154742 | Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy. | 2007 Dec 17 |
1 |
| 9 |
17109677 | Rimonabant: endocannabinoid inhibition for the metabolic syndrome. | 2006 Dec |
1 |